BASEL, 18-Jul-2018 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA)…
Designation based on phase III HAVEN 3 study demonstrating Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis First medicine…
BASEL, 20-Mar-2018 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its…
DUBLIN, 16-Jan-2018 — /EuropaWire/ — At Shire, we’ve been committed to the hemophilia community and the lives of every patient afflicted…
Roche to acquire Ignyta for US$ 27.00 per share Ignyta’s investigational medicine entrectinib, a selective CNS-active tyrosine-kinase inhibitor being developed…
New study combining Esbriet (pirfenidone) and nintedanib showing similar safety profile for the combination treatment to that expected for each…
BASEL, 14-Sep-2017 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data for the phase III BRIM8 study, which…
Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine HAVEN 1…
First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based…
First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy…
Data presentations will include platform sessions and posters across relapsing multiple sclerosis and primary progressive multiple sclerosis BASEL, 24-Apr-2017 —…
New results from the phase III GALLIUM study which compared Gazyva/Gazyvaro (obinutuzumab) plus chemotherapy to Rituxan/ MabThera (rituximab) plus chemotherapy…
15 oral presentations from 17 abstracts across six autoimmune conditions First presentation of Actemra/RoActemra data from GiACTA - the largest…
OCREVUS is the first investigational medicine seeking marketing authorisation for both relapsing and primary progressive multiple sclerosis (MS) FDA grants…
Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for…
19 Roche medicines are included in more than 200 abstracts during ASCO 2016 New results for cancer immunotherapy atezolizumab in…
In the pivotal study, treatment with Gazyvaro plus bendamustine chemotherapy reduced the risk of disease worsening or death by 52…
cobas 6800/8800 Systems offer fastest time to results and highest throughput of any molecular platform, helping to improve disease management…
BASEL, 12-8-2015 — /EuropaWire/ — Today (11 August 2015), Roche welcomed 100 European university students from 34 countries studying science…
The Perjeta regimen is the first neoadjuvant (pre-surgery) breast cancer treatment recommended for approval in the EU based on the…
The Roche test enables healthcare professionals to identify patients with a suspected heart attack in the pre-hospital setting, helping ensure…
40 data presentations across 7 autoimmune conditions, including new results from RoACTEMRA in early RA and systemic sclerosis (SSc) –…
Second FDA Breakthrough Therapy Designation for MPDL3280A following bladder cancer in 2014 BASEL, 3-2-2015 — /EuropaWire/ — Roche (SIX: RO,…
BASEL, 3-2-2015 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender…
BASEL, 12-1-2015 — /EuropaWire/ — Collaboration leverages both companies’ strengths to advance the progress of personalized treatments for patients with…
BASEL, 3-12-2014 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the acquisition of Ariosa Diagnostics, Inc. (Ariosa),…
First new treatment option for women in Europe in more than 15 years for most difficult to treat form of…
Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib BASEL, 11-7-2014 — /EuropaWire/…
Basel, 04-6-2014 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the acquisition of Genia Technologies, Inc. (Genia), a privately…
Expanded indication makes cobas HPV Test the only test approved in U.S. that can be used instead of Pap in…
First anti IL-6 receptor biologic now available for subcutaneous and intravenous administration for both monotherapy and combination therapy Basel, 29-4-2014 —…
Investment to help meet rising demand for licensed biologics and expected pipeline growth Basel, Switzerland, 16-10-2013 — /EuropaWire/ — Roche (SIX: RO,…
Erivedge is a new medicine that helps people with a disfiguring and potentially life-threatening form of skin cancer 19-7-2013 —…
New test expands cancer diagnostics portfolio and strengthens Roche Diagnostics’ comprehensive tumour marker menu 19-7-2013 — /europawire.eu/ — Roche (SIX: RO,…
Tests support long-term routine management of organ transplant recipients and enhanced workflow in medical labs 19-7-2013 — /europawire.eu/ — Roche…